Skip to main content
Clinical Trials/CTRI/2025/04/084589
CTRI/2025/04/084589
Not yet recruiting
Phase 2

AN OPEN LABEL STUDY TO ASSESS THE EFFECTIVENESS OF SARSAPARILLA OFFICINALIS 3X IN URINARY TRACT INFECTION BY ESTIMATING PUS CELLS

Metropolitan Homoepathic Medical College and Hospital1 site in 1 country53 target enrollmentStarted: April 20, 2025Last updated:

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Metropolitan Homoepathic Medical College and Hospital
Enrollment
53
Locations
1
Primary Endpoint
Pre post changes in pus cell count in routine examination of urine

Overview

Brief Summary

This study is an open label, single arm study to assess the effectiveness of Homoeopathic medicine Sarsaparilla 3x among 53 patients by estimating pre-post changes in pus cells in Routine urine examination. Sarsaparilla 3x will be administered twice daily and the dose and repetition will be done based on UTISA scoring. Primary outcome includes pus cells estimation in routine urine examination at baseline, at 7th day and again at 14th day. For secondary outcome UTISA questionnaire scoring is to be assessed at baseline , 7th day and 14th whereas Total Leucocyte Count (TLC) only at baseline and 14th day.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 45.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Diagnosed cases of urinary tract infection and/or with clinical features of UTI of age group 18- 45years,in females irrespective of their socio-economic status.
  • Patients having pus cells in urine greater than 10/HPF.
  • Subjects agree to comply with the protocol.

Exclusion Criteria

  • Patients associated with conditions like myocardial infarction, renal failure, hepatic failure, malignancies and metabolic disorders like diabetes mellitus with clinical evidences and complicated cases of UTI such as pyelonephritis, urethral stricture, sepsis with clinical evidences.
  • Patients are unconscious, ambulatory, too sick for consultation, differently abled, terminally or critically ill patients, mentally incompetent people, unstable mental or psychiatric illness.
  • Already taking treatment for any other chronic diseases.
  • Patient who has been dealing with urinary symptoms with several modern medication.
  • Pregnant and lactating mothers.
  • Catheter induced UTI.
  • Self-reported immune-compromised state.

Outcomes

Primary Outcomes

Pre post changes in pus cell count in routine examination of urine

Time Frame: Pre post changes in pus cell count in routine examination of urine, 2 weeks from baseline

Secondary Outcomes

  • UTI Symptom Assessment questionnaire, TLC in CBC report(2 weeks)

Investigators

Sponsor
Metropolitan Homoepathic Medical College and Hospital
Sponsor Class
Private medical college
Responsible Party
Principal Investigator
Principal Investigator

Shreya Shee

Metropolitan Homoeopathic Medical College and Hospital

Study Sites (1)

Loading locations...

Similar Trials